A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)Feng Wang, Rui‐Hua Xu, Ming-Ming He et al.|Clinical Cancer Research|2022Cited by 60
A phase III study of comparing FOLFOX+/-bevacizumab with FOLFOX+/-bevacizumab+ high-dose intravenous vitamin C as first-line therapy in patients with advanced colorectal cancer.Feng Wang, Rui‐Hua Xu, Weijia Fang et al.|Journal of Clinical Oncology|2020Cited by 2
Data from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)Feng Wang, Rui‐Hua Xu, Ming-Ming He et al.|Unknown|2023Cited by 0
Supplementary Data from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)Feng Wang, Rui‐Hua Xu, Ming-Ming He et al.|Unknown|2023Cited by 0
Supplementary Figure from A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)Feng Wang, Rui‐Hua Xu, Ming-Ming He et al.|Unknown|2023Cited by 0